Stocks · News reference
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
A longitudinal study published in The Lancet Neurology using Alamar Biosciences' NULISAseq CNS 120 panel found that patients receiving lecanemab for early symptomatic Alzheimer's disease show markedly different biological responses. The research revealed that biomarkers associated with amyloid clearance differ from those associated with cognitive decline, explaining why clearing amyloid doesn't produce uniform clinical benefits across patients. The study measured 130 plasma proteins across 2,385 samples from 1,967 participants.
Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed as the Dow fell 150 points; Mistras surged on a $20.35/share buyout deal, while crypto and tech stocks gained.
Top 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.